A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study
1986/05/01 by George Omura, John A. Blessing, Clarence E. Ehrlich +5 · 17 citations
Medicine · #Ovarian cancer diagnosis and treatment #Reproductive Biology and Fertility
paper · pdf · doi:10.1002/1097-0142(19860501)57:9<1725::aid-cncr2820570903>3.0.co;2-j
Abstract
A randomized clinical trial was conducted in women with bulky (suboptimal) Stage III and Stage IV ovarian carcinoma, using doxorubicin (Adriamycin) and cyclophosphamide with or without cisplatin. There were 440 evaluable cases, of which 227 had measurable disease. One hundred twenty of these latter patients were treated with cyclophosphamide and doxorubicin (CA), while 107 received cyclophosphamide, doxorubicin and cisplatin (CAP). The clinical complete response (CR) rate for CA was 26% (31/120) compared with 51% (55/107) for CAP (P = less than 0.0001). Of 23 CRs receiving CA who had a second-look laparotomy, only four were negative; of 39 CRs receiving CAP and a second-look, 13 were negative (not statistically significant). The response duration for patients with measurable disease (median 14.6 versus 8.8 months), progression-free interval for all patients (13.1 versus 7.7 months), and survival for patients with measurable disease (19.7 versus 15.7 months) showed a statistically significant advantage for CAP; however, there was no difference in survival of patients with nonmeasurable disease. Toxicity was more severe with CAP but was tolerable. Thus, the addition of cisplatin improves the chemotherapy of advanced ovarian carcinoma.
Cited by
- Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. [europepmc]
- Progress in gynecologic cancer research: the Gynecologic Oncology Group experience. [europepmc]
- Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role. [europepmc]
- Overcoming platinum resistance in ovarian carcinoma. [europepmc]
- Rethinking ovarian cancer: recommendations for improving outcomes. [europepmc]
- Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. [europepmc]
- Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. [europepmc]
- Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study. [europepmc]
- Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer. [europepmc]
- Functional Analyses of RUNX3 and CaMKIINα in Ovarian Cancer Cell Lines Reveal Tumor-Suppressive Functions for CaMKIINα and Dichotomous Roles for RUNX3 Transcript Variants. [europepmc]
- Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer. [europepmc]
- Chemotherapy Resistance in Advanced Ovarian Cancer Patients. [europepmc]
- Malignant transformation arising from mature ovarian cystic teratoma: A case series. [europepmc]
- Diagnostic accuracy of 18 F-FDG PET/CT scan for peritoneal metastases in advanced ovarian cancer. [europepmc]
- Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor. [europepmc]
- Pretreatment Nutritional Status in Combination with Inflammation Affects Chemotherapy Interruption in Women with Ovarian, Fallopian Tube, and Peritoneal Cancer. [europepmc]
- Tailored Treatment Strategies in First Line Therapy for Ovarian Cancer Patients: A Critical Review of the Literature. [europepmc]
Related